用于新型冠状病毒肺炎防治的生物制品研究策略

新型冠状病毒，又称严重急性呼吸综合征冠状病毒2（severe acute respiratory syndrome coronavirus 2, SARS-CoV-2），它引起的新型冠状病毒肺炎（coronavirus disease 2019, COVID-19）目前已成为全球关注的突发公共卫生事件。SARS-CoV-2感染人数众多，传播性极强，病死率较高，亟需寻求安全高效的特异制剂用于病毒感染的防治。目前在烈性传染病防治中广泛应用的生物制品，在阻断SARS-CoV-2感染上同样极具潜力。本文根据严重急性呼吸综合征（severe acute respiratory syndrome, SARS）和中东呼吸综合征（Middle East respiratory syndrome, MERS）已有的防治策略及研发进展，对干扰素、恢复期血浆、肠道微生态调节剂、疫苗、抗体等生物制品的应用经验和研发命运进行综述，为早日攻克COVID-19提供依据。

Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019

Coronavirus disease 2019 (COVID-19) caused by the novel coronavirus, also known as severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), has become a Public Health Emergency of International Concern. Due to the large infection population, broad transmissibility and high mortality, it is urgent to find out the efficient and specific methods to prevent and treat COVID-19. As biological products have broadly applied in the prevention and treatment of severe epidemic diseases, they are promising in blocking novel coronavirus infection. According to the research advances of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), we reviewed the potential application of biological products such as interferon, convalescent plasma, intestinal micro-ecological regulators, vaccines and therapeutic antibodies, etc. , on prevention and treatment of COVID-19. May this review be helpful for conquering COVID-19 in the near future.